MITRAL VALVE REGURGITATION
Mitral Valve Regurgitation (or MR) is one of the most prevalent heart diseases, caused by structural damage of the mitral valve. In the US alone, more than 5 million people are affected, with 250,000 new diagnoses every year.
TREATMENT CHALLENGES
Underdiagnosed and Undertreated
04
Enterprise
This is the space to introduce the Services section. Briefly describe the types of services offered and highlight any special benefits or features.
01
The Clinical Standard
For decades, interventions have been conducted via open heart surgery under use of a heart lung machine. While generally safe and effective, open heart interventions are complex and resource-intensive, entailing a high degree of trauma and consequential recovery burden.
02
The Treatment Gap
MR remains an undertreated disease, as many patients are not eligible for surgery because they are considered to be in either too early or too late a stage to be operated.
03
The Shift to TMVr
With the advent of transcatheter technology, a new treatment paradigm is addressing this problem, shifting the treatment from heart surgery to interventional cardiology operations: Transcatheter Mitral Valve Repair (TMVr).
The Growing Burden of Disease
5 Million+
People affected in the US alone.
100,000
Patients annually undergoing interventions (US & EU).
10%
Prevalence rate in the 75+ age group.
